Valuation: Alcon

Market Cap 33.26B 29.28B 27.01B 25.26B 47.33B 3,135B 48.21B 325B 126B 1,546B 125B 122B 5,380B P/E 2026 *
31.6x
P/E 2027 * 24.6x
Enterprise Value 35.86B 31.57B 29.12B 27.23B 51.03B 3,380B 51.98B 350B 136B 1,667B 135B 132B 5,801B EV / Sales 2026 *
3.22x
EV / Sales 2027 * 2.94x
Free-Float
97.36%
Yield 2026 *
0.52%
Yield 2027 * 0.6%
Manager TitleAgeSince
Chief Executive Officer 60 01/07/2018
Director of Finance/CFO 58 08/04/2019
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 60 -
Chairman 70 01/07/2018
Director/Board Member 63 01/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 32.1B
+0.27%-3.52%-30.45%+0.62% 87.99B
+4.05%+5.81%-2.96%-26.14% 12.9B
+0.52%+2.52% - - 9.42B
-0.60%-11.05%-7.26%+526.69% 2.18B
-2.69%-2.95%-27.79%-63.31% 1.47B
-2.27%-6.98%-44.88%-33.25% 847M
+0.15%+4.65%+9.21%-6.32% 789M
+2.55%+4.53%+52.86%-32.86% 735M
+0.26%+2.10%+7.46%-11.19% 386M
Average +0.22%-1.06%-5.48%+44.28% 12.97B
Weighted average by Cap. +0.51%-2.06%-25.75%+6.64%

Financials

2026 *2027 *
Net sales 11.13B 9.8B 9.04B 8.45B 15.83B 1,049B 16.13B 109B 42.06B 517B 41.77B 40.87B 1,800B 11.82B 10.41B 9.6B 8.98B 16.82B 1,114B 17.13B 115B 44.68B 550B 44.38B 43.41B 1,912B
Net income 1.09B 955M 881M 824M 1.54B 102B 1.57B 10.59B 4.1B 50.45B 4.07B 3.99B 176B 1.38B 1.21B 1.12B 1.05B 1.96B 130B 2B 13.46B 5.22B 64.15B 5.18B 5.07B 223B
Net Debt 2.6B 2.29B 2.11B 1.97B 3.7B 245B 3.77B 25.36B 9.82B 121B 9.76B 9.55B 420B 1.54B 1.36B 1.25B 1.17B 2.2B 146B 2.24B 15.07B 5.84B 71.78B 5.8B 5.67B 250B
Logo Alcon
Alcon Inc. is the global leader in the design, manufacture and marketing of ophthalmic care products. Net sales break down by category of products as follows: - ophthalmic surgical products and equipment (55.7%): consumables (52.7% of net sales), implantable products (31%) and other products (16.3%; in particular surgical equipment) for the treatment of cataracts, retinal diseases, glaucoma and refractive errors; - vision care products (44.3%): contact lenses (60.6% of sales) and eye care products (39.4%; eye drops and ophthalmic ointments, etc.). At the end of 2025, the group operated 17 production sites worldwide. Net sales are distributed geographically as follows: Switzerland (0.7%), the United States (45.1%), Japan (5.9%), China (5.5%), and Other (42.8%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AAA